Kronos Bio Inc reports results for the quarter ended in December - Earnings Summary

Kronos Bio

21/03/2024 12:38

* Kronos Bio Inc  KRON.OQ  reported a quarterly adjusted
loss
of 34 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -56 cents.  The mean expectation of
four analysts for the quarter was for a loss of 52 cents per
share. Wall Street expected results to range from -60 cents
to -48 cents per share.
    * Revenue was $2.29 million​; analysts expected $1.53
million. 
    * Kronos Bio Inc's reported EPS for the quarter was a loss
of 43
cents​.
    * The company reported a quarterly loss of $25.32 million.
    * Kronos Bio Inc shares had fallen by 3.2% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Kronos Bio Inc is
$4.25 
This summary was machine generated from LSEG data March 21 at
12:37 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.52          -0.34          Beat
 Sep. 30 2023      -0.51          -0.54          Missed
 Jun. 30 2023      -0.46          -0.52          Missed
 Mar. 31 2023      -0.44          -0.46          Missed